GuoLine Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

GuoLine Advisory’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-79,700	Closed	-$38.6M	–	23
2025 Q1	$38.6M	Hold	79,700	–	–	4.09%	10
2024 Q4	$32.1M	Hold	79,700	–	–	3.31%	15
2024 Q3	$37.1M	Hold	79,700	–	–	3.77%	11
2024 Q2	$37.4M	Hold	79,700	–	–	3.99%	13
2024 Q1	$33.3M	Hold	79,700	–	–	4.06%	13
2023 Q4	$32.4M	Buy	+79,700	New	+$29.4M	5.13%	12

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GuoLine Advisory's VRTX Position: Q2 2025 in Review

GuoLine Advisory sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 79,700 shares — an estimated $38.6M sold.

GuoLine Advisory first reported a position in VRTX in Q4 2023 and held it in 6 quarters. The position peaked at $38.6M in Q1 2025. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

GuoLine Advisory reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
GuoLine Advisory sold 79,700 Vertex Pharmaceuticals shares in Q2 2025, an estimated $38.6M.
GuoLine Advisory first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 6 quarters.
GuoLine Advisory's Vertex Pharmaceuticals position peaked at $38.6M in Q1 2025.
1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on GuoLine Advisory's 13F filing for Q2 2025, filed 7 Jul 2025.